{
    "links": "https://www.ycombinator.com/companies/arpeggio-bio",
    "name": "Arpeggio Bio",
    "headline": "Arpeggio Bio develops drugs targeting transcription factors using AI\u00e2\u0080\u00a6",
    "batch": "S19",
    "description": "Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted \"undruggable\" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.",
    "activity_status": "Active",
    "website": "http://www.arpeggiobio.com",
    "founded_date": 2018.0,
    "team_size": 20.0,
    "location": "Boulder, CO",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:biotech; industry:genomics; industry:drug-discovery",
    "founders": [],
    "status": true,
    "generated_description": "**Arpeggio Bio** is a cutting-edge biotech company that combines artificial intelligence with high-throughput RNA sequencing to take on the challenging world of *transcription factors* in drug development. Founded in 2018 and based in Boulder, Colorado, Arpeggio is part of Y Combinator's Batch S19 and has successfully raised $20 million in venture capital to further its mission.\n\nAt the core of what Arpeggio Bio does is their innovative platform targeting \"undruggable\" proteins such as NRF2, TEAD, and GPX4. Their lead program is currently racing towards a Development Candidate (DC) aimed at treating immune-oncology resistant melanoma\u2014a testament to their ambition in the fiercely competitive pharmaceutical landscape.\n\nThe team, comprised of about 20 talented individuals, has established notable collaborations with prestigious companies like Johnson & Johnson and FORMA, demonstrating early validation of their platform's efficacy in fields like rare disease and inflammation. With promising results from a significant Phase I clinical trial, the future looks optimistic.\n\nArpeggio's vision goes beyond just single-target drugs; they\u2019re designing medicines that consider the biological network as a whole. They\u2019ve already generated over 250,000 chemotranscriptomes and measured more than 2.3 billion mRNAs, positioning themselves as leaders in transcriptomic research.\n\nCurrently, Arpeggio is pioneering solutions to combat drug resistance in chronic diseases, including cancer and neurodegeneration. With two drug programs in their pipeline, they aim to tackle issues that affect a substantial portion of the adult population, especially as chronic diseases are projected to impact nearly all adults over fifty by 2040.\n\nIn the ever-evolving landscape of biotech, Arpeggio Bio stands out as a unique player, merging advanced technology with a commitment to innovate in drug discovery. For more details, you can explore their website at [Arpeggio Bio](http://www.arpeggiobio.com).\n\n### Summary\n- **Founded**: 2018\n- **Location**: Boulder, CO\n- **Funding**: $20M in venture capital\n- **Team**: 20 employees\n- **Key Partnerships**: Johnson & Johnson, FORMA\n- **Focus**: \"Undruggable\" proteins and AI-driven drug development\n- **Pipeline**: Drugs for chronic diseases, including cancer\n- **Website**: [www.arpeggiobio.com](http://www.arpeggiobio.com)",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/2a92a43f4c6695a5597dc1d2bf761a3b1eab579e.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAKBB576US%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191004Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJHMEUCIFRjVxB%2FHxIJHUHkMazoRi02jYmaJVJGr3K7C9j9jiflAiEA6iszI4%2Fpn8hDzk7aMP6LlnqynbPgCG20CpdZqslTFdsq7gMI3P%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAAGgwwMDYyMDE4MTEwNzIiDNVC6v4lNMvTlUOjTyrCA7R4NjcD6pWk9Gjux5NdrMhwU67pNo%2F0JVDzkHcTjBsajnWXpXoyD3m%2FssX0rwYmnUDJB9VTgD%2FW2M8cWxeD93WFxLjs25juzzGj1%2BC1Ky9E0oNPwn5jGw%2BjokWylkxcouU18mjUtP8juH4uF9Xfmm%2FMAgvOPsNSAaYBQ%2BdA5Vwom66MCzynAPEJs6Nqxd5FqtgiiWFRhT5L9g%2FvfLTKqpdIg0XPF6s95lLCtwWDHST72Bn9JVH2zZmqjTgO2sao7Rg4M%2BPIRazg8JhbPoWk6xsB2yfG1f%2Bs8AFVxihyUnQj6TUnhrhezs7WYsaTfaaAoTIzhEsLwJDqBQDSptmSlUj%2BQ3KWwrXpJIm0b1uOmaylnrEpn5obECdRc%2FzdEfNt6DNEE5cbUhQo8Gjfd6MWfyV7JHtX7DwsLMssQPKNZ6qWJq2gP1fVHFkz5K0F%2F73p54AKB5gCkyOeRPJHmAzYMdfZpMF%2B8hE4eZU6k7m1EqPLEW2F9HVvcqPFp8T%2BZgbbDLBVWICSdX%2FfJ%2BniwyC72aHLaqjCxHLvJ6WyAawaepaDD9csEvz4DYD9lpHx9hJXqrFDyrT1vAaaBwuoXgulZ6gNmjCmiuO9BjqlATnnhPFnQUT7QmhXwrAFbGCqdgkRFIVCdDrNmasZJtz86frmIpB%2BlwZjavL0FMq46mN9RKFTuRNdMnOtOh1adMI%2BkC%2F%2Bs3m8pwR56JxErG%2B8nIBe7efeu5WiUZbGCsp85oXBCGY%2FoP1uWrJo843L0LVdmjtyXaDurxXSgzfeZo2RDONME7LNkPzuGzA19XefIc9OvA1QFcZr3VIdZe%2BLywfFgDpgwA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=573fba9928f2e6cc8e0f88c793902ee1873ac78eeb838adbccfe337213e94d99",
    "social_links": [
        "https://twitter.com/ArpeggioBio"
    ],
    "logo_path": "data/logos\\Arpeggio_Bio_logo.png"
}